NCT07144241View on ClinicalTrials.gov

Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) Therapy for Type 2 Diabetes Mellitus Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

July 1, 2026

Conditions
Type 2 Diabetes Mellitus
Interventions
BIOLOGICAL

Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy

The intervention group will receive standard DM therapy plus an exosome combination of 1 vial Exo-HWS + 1 vial Exo-HUVEC, administered monthly for three months via intravenous bolus injection.

BIOLOGICAL

Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy

The control group will receive standard DM therapy plus 1 vial Exo-HWS, administered monthly for three months via intravenous bolus injection.

Trial Locations (1)

Unknown

UNIMUS Hospital, Semarang

All Listed Sponsors
lead

Indonesia University

OTHER